Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Oliver Gautschi(Université Toulouse III - Paul Sabatier), Adrian F. Ochsenbein(University of Bern), Daniel Rauch(Washington University in St. Louis), Miklos Pless(Ontario Institute for Cancer Research), Rolf A. Stahel(International Breast Cancer Study Group), Nicolas Mach(University of Geneva), Thilo Zander(Luzerner Kantonsspital), Martina Schneider(Valneva (Austria)), Martin Früh(University of Bern), Richard Cathomas(Kantonsspital Graubünden), Solange Peters(University Hospital of Lausanne), Christine Biaggi(Swiss Group For Clinical Cancer Research), Alfred Zippelius(University of Basel), Patrizia Froesch(Institute of Oncology Research), Klazien Matter‐Walstra(University of Basel), Daniel Betticher, Qiyu Li(Army Medical University), Sacha I. Rothschild(University Hospital of Basel)
Cited by 10
Related Papers
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k